Niterra Invests in Remote Patient Monitoring Startup Vivalink to Accelerate Development and Deployment of Innovative Healthcare Solutions
November 10, 2023 : Niterra, a global venture capital firm focused on innovative healthcare technologies, announced today that it has invested in Vivalink, a remote patient monitoring (RPM) startup.
FDA Approves New Obesity Drug Zepbound, First to Activate Two Key Hormone Receptors
November 10, 2023 : The Food and Drug Administration (FDA) has approved Eli Lilly’s Zepbound™ (tirzepatide) for chronic weight management, making it the first and only FDA-approved drug that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) hormone receptors.
